Management of Adverse Events in Early Clinical Trials by Advanced Practice Providers in the Outpatient Setting: The University of Texas MD Anderson Cancer Center Experience
Authors:
- PhD Fedricker D. BarberPBPhD Fedricker D. Barber
- Msn Victoria A. MillerMMMsn Victoria A. Miller
- Dnp Gabriele E. UrshelDUDnp Gabriele E. Urshel
Open Access
- 12 October 2022
- journal article
- research article
- Published by Harborside Press, LLC in Journal of the Advanced Practitioner in Oncology
- Vol. 13 (7) , 664-672
Abstract
Background: Advanced practice providers (APPs) play important roles in enrolling, educating, and caring for patients in clinical trials. However, much remains unknown about the role of APPs in managing adverse events (AEs) in early (phase I to II) clinical trials. In this study, we assessed the outpatient management of grade 3 to 4 AEs by APPs in early trials and characterized the workflow of our APP Phase I to II Fast Track (FT) Clinic. Patients and Methods: We retrospectively reviewed records of patients with advanced or metastatic solid tumors enrolled in phase I to II clinical trials who were seen by APPs from September 2017 to August 2018 in the APP phase I to II FT clinic in the Department of Investigational Cancer Therapeutics. Results: A total of 808 patients enrolled in 159 clinical trials were seen in 2,697 visits (median 3 visits per patient; range 1–28) by 10 APPs. Treatment was interrupted in 6.9% of visits, and grade 3 to 4 AEs were seen in 5.4% of visits; however, patients from 1.4% of visits were sent to the emergency center (EC) and/or admitted. Patients referred to the EC and/or admitted were more likely to have baseline hypoalbuminemia, high lactate dehydrogenase, and poor Eastern Cooperative Oncology Group performance status (i.e., ECOG > 1; p < .001). There were no associations between EC referral and gender, APP years of experience, or type of treatment. Conclusions: The APP Phase I to II FT Clinic has an important role in the management of AEs by APPs in early clinical trials in the outpatient setting, potentially avoiding EC visits and admissions.Keywords
This publication has 29 references indexed in Scilit:
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- Checkpoint Inhibitors: Common Immune-Related Adverse Events and Their ManagementClinical Journal of Oncology Nursing, 2017
- Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor TherapyFrontiers in Pharmacology, 2017
- Education and training of clinical and translational study investigators and research coordinators: A competency-based approachJournal of Clinical and Translational Science, 2017
- Phase I Cancer Trials and Palliative Care: Antagonism, Irrelevance, or Synergy?Journal of Pain and Symptom Management, 2016
- Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/LTumor Biology, 2016
- Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancerOncoTargets and Therapy, 2015
- Outcomes Evaluation of a Weekly Nurse Practitioner-Managed Symptom Management Clinic for Patients With Head and Neck Cancer Treated With ChemoradiotherapyOncology Nursing Forum, 2013
- A Nurse Practitioner-Led Urgent Care Center: Meeting the Needs of the Patient With CancerClinical Journal of Oncology Nursing, 2013
- Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer CenterCancer, 2011